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Abstract
Study Objectives: Multiple methods for monitoring sleep-wake activity have identified sleep disturbances as risk factors for
Alzheimer disease (AD). In order to identify the level of agreement between different methods, we compared sleep parameters
derived from single-channel EEG (scEEG), actigraphy, and sleep diaries in cognitively normal and mildly impaired older adults.
Methods: Two hundred ninety-three participants were monitored at home for up to six nights with scEEG, actigraphy, and sleep
diaries. Total sleep time (TST), sleep efficiency (SE), sleep onset latency (SOL), and wake after sleep onset (WASO) were calculated
using each of these methods. In 109 of the 293 participants, the ratio of cerebrospinal fluid concentrations of phosphorylated tau
(p-tau) and amyloid-β-42 (Aβ42) was used as a biomarker for AD pathology.
Results: Agreement was highest for TST across instruments, especially in cognitively normal older adults. Overall, scEEG and
actigraphy appeared to have greater agreement for multiple sleep parameters than for scEEG and diary or actigraphy and diary.
Levels of agreement between scEEG and actigraphy overall decreased in mildly impaired participants and those with biomarker
evidence of AD pathology, especially for measurements of TST.
Conclusions: Caution should be exercised when comparing scEEG and actigraphy in individuals with mild cognitive impairment
or with AD pathology. Sleep diaries may capture different aspects of sleep compared to scEEG and actigraphy. Additional studies
comparing different methods of measuring sleep-wake activity in older adults are necessary to allow for comparison between
studies using different methods.

Statement of Significance
Sleep-wake activity may be monitored using a number of different instruments. In this study, sleep-wake activity was monitored in
293 cognitively normal and mildly impaired older adults for up to 6 nights using three different methods simultaneously: (1) singlechannel EEG device worn on the forehead; (2) actigraphy; (3) sleep diary. Participants also underwent standardized cognitive assessments and a subset of 109 participants had CSF Alzheimer disease (AD) biomarkers measured. This is one of the largest cohorts
comparing subjective and objective sleep monitoring methods over multiple nights, and no previous study has participants as wellcharacterized for both cognitive function and CSF AD biomarkers. Understanding how different sleep instruments measure sleepwake activity in older adults with and without evidence of AD will help the sleep field compare studies using different methods.
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Introduction

Methods
Study design
Participants were enrolled in an ongoing longitudinal observational study of aging and AD at the Knight Alzheimer Disease
Research Center at Washington University in St. Louis, MO. Sleep
data included in this analysis was collected from 2013 to 2019.
Participants were ≥60 years old and underwent a clinical assessment that included the Clinical Dementia Rating (CDR) [41] and
Mini Mental State Examination (MMSE) [42]. Participants were
included if they scored CDR 0 (cognitively normal) or CDR 0.5
(very mild AD dementia).

Sleep monitoring
The protocols for sleep monitoring in this study have been previously described [7, 43, 44]. Sleep was assessed over six nights
at home using three instruments simultaneously: scEEG (Sleep
Profiler, Advanced Brain Monitoring, Carlsbad, CA), actigraphy
(Actiwatch2, Philips Respironics, Andover, MA), and sleep
diaries. Actigraphy and sleep diaries were used to confirm that
the scEEG recorded the entire sleep period. The scEEG device was
worn on the forehead and recorded at 256 samples per second
from three frontal sensors placed at approximately AF7, AF8, and
Fpz. Only the AF7-AF8 channel was used for scoring. The scEEG
hardware applies a 0.1 Hz low-frequency filter and a 67 Hz highfrequency filter. The scEEG studies were scored by registered
polysomnographic technologists using modified American
Academy of Sleep Medicine (AASM) criteria [20]. Actigraphy data
were processed using Actiware (Phillips Respironics) with the
wake threshold at the “low” setting of 20, which has been shown
to correspond best with PSG [23]. Total sleep time (TST), sleep
efficiency (SE), sleep onset latency (SOL), and WASO were calculated using the data from each instrument.
Participants were instructed to complete the sleep diary
every morning upon awakening and documented bedtime,
wake-up time, TST, how long it took to fall asleep (SOL), number
of nighttime awakenings, and occurrence of unusual events that
may impact sleep. Since SE and WASO were not recorded by the
participants, we calculated diary SE by dividing reported TST by
reported time in bed (TIB; time between bedtime and wake-up
time) and diary WASO by subtracting TST and SOL from TIB.
A minority of participants had SE and WASO parameters calculated using the sleep diary that led to SE >100% (17 participants,
76% CDR 0) and WASO <0 minutes (83 participants, 80% CDR 0).
These data were kept in the analysis since they were actual participant responses on the questionnaire with the exception of
one participant whose diary-calculated SE for a single night was
an extreme outlier.
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Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid plaques in
the brain, intracellular tangles of tau, synaptic and neuronal loss,
cognitive dysfunction, and eventual dementia [1, 2]. Sleep disturbance is common in AD with reports that around 40% of patients
with AD suffer from sleep problems [3]. Changes in sleep comprise
an important component of disability and lifestyle disruption for
the elderly and their caretakers, increasing the risk of early institutionalization [4]. Given the rising prevalence of AD, there has been
increasing interest in identifying additional early markers of AD
pathology. Sleep disturbance is hypothesized to be both an early
marker of preclinical AD as well as a risk factor for developing
AD pathology itself [5, 6]. Polysomnographic, actigraphic, and
subjective evidence have all demonstrated sleep disturbance associated with early symptomatic AD (this term encompasses individuals labeled with mild cognitive impairment (MCI) due to AD
and very mild AD dementia or with preclinical AD) [7–13]. Changes
in sleep duration with aging have been associated not only with
cognitive impairment, but also with premature mortality [14], cardiovascular disease [15], and physical frailty [16, 17]. Further investigation is needed, but the challenge remains to identify the
optimal diagnostic tools for assessing sleep in the elderly on a
large scale while balancing ease of use, accuracy of measurement,
and cost-effectiveness.
Attended polysomnography (PSG) in a sleep laboratory is the
gold standard for assessing sleep [18]. However, PSG can be costly
as well as inconvenient for older adults due to the need to travel
outside the home. Furthermore, sleeping in a new, unfamiliar environment can be disruptive to sleep and serves as the basis for
the “first night” effect seen with PSG [19]. Other objective instruments that allow testing in the naturalistic home environment
such as single-channel EEG (scEEG) and wrist-worn actigraphy
have been investigated as alternative and/or supplementary
methods of measuring sleep accurately and accessibly. scEEG is
a noninvasive forehead-worn device that allows for measuring
sleep stages with one frontal EEG channel. Previous work has
demonstrated that scEEG has a high level of agreement with
PSG for sleep staging and measuring sleep parameters, with the
caveat that scEEG appears to have more difficulty determining
transitions between sleep-wake stages, and agreement with
PSG worsens with increased sleep fragmentation [20–22]. Wristworn actigraphy relies on the user’s movement activity to estimate sleep and wakefulness. It has been well-described as a
valid method of measuring sleep in comparison to PSG [23, 24],
though it is not validated for staging sleep and may be prone
to overestimation of sleep due to difficulties in distinguishing
motionless wake from sleep [25]. In one study of healthy young
adults from Japan [26], scEEG had greater correlation and agreement with PSG than actigraphy for certain sleep parameters
such as wake after sleep onset (WASO). However, studies performing similar comparisons in older adults are needed.
Subjective measures of sleep are important in assessing
sleep. However, studies comparing objective sleep (including as
assessed by PSG) to subjective sleep diaries or questionnaires in
both younger adults and cognitively normal older adults have
found limited association between instruments, especially in regards to perceived sleep quality [27–35]. For sleep measurements
that were found to correlate, agreement assessed by BlandAltman plots was generally poor [27, 34, 36, 37]. Little association

between subjective and objective sleep has been demonstrated
in patients with early symptomatic AD [38–40]. Further, many
of the studies in older adults comparing one objective to one
subjective instrument have been limited by sample sizes of
less than 100 participants. Our study is a cross-sectional analysis of a cohort of nearly 300 cognitive normal or very mildly
symptomatic participants ≥60 years old that aims to compare
the level of agreement for three at-home sleep-wake monitoring
instruments.

Chou et al. |

Cerebrospinal fluid biomarkers
Cerebrospinal fluid (CSF) was collected under a standardized protocol [45] within one year of sleep monitoring [44].
Participants underwent a fasting morning lumbar puncture and
CSF was collected by gravity drip and stored in polypropylene
tubes at -80°C until analysis. CSF total tau, phosphorylated
tau-181 (p-tau), and amyloid-β-peptide 42 (Aβ42) were measured using an automated electrochemiluminescence immunoassay (Elecsys immunoassay on the cobas e 601 analyzer, Roche,
Indianapolis, IN, USA). The ratio of CSF p-tau to Aβ42 (p-tau/
Aβ42) was calculated as a measure of AD pathology using previously defined cutoffs [45]: a higher CSF p-tau/Aβ42 ratio signifies
more AD pathology [46].

Intraclass correlation coefficients (ICCs) were calculated for
each sleep parameter and instrument pair (scEEG vs. actigraphy,
scEEG vs. diary, actigraphy vs. diary), and are sensitive to differences in the means of the observations and are a measure of
interobserver agreement [48]. ICC values of <0.5, 0.5–0.75, 0.75–
0.9, and >0.9 indicate poor, moderate, good, and excellent reliability, respectively [49]. One-way analysis of variance (ANOVA)
were used to compare group differences (e.g. CDR 0 vs. CDR 0.5)
in sleep parameters (e.g. TST, SE, etc.) measured by the same instrument (e.g. scEEG). Finally, Bland-Altman plots were generated for all sleep parameters and instrument comparisons [50].
Bivariate Pearson correlation coefficients were calculated to assess linear relationships between instruments and
these results are available in the Supplementary Materials
(Supplementary Table 3, Supplementary Figures 1–6).
All statistical analyses were performed using SPSS version 26 (IBM Corporation, Armonk, NY). Bland-Altman plots,
scatterplots, and linear regression best-fit lines were created on
GraphPad version 8.4.2 for Mac (GraphPad Software, San Diego,
CA). Statistical significance was set at p < 0.05.

Results
Demographics

Data analysis
We included participants who had data available for at least
2 nights with all of the three instruments and calculated the
average of each sleep parameter for use in our analysis. Paired
sample t-tests were used to calculate mean differences and 95%
confidence intervals (CIs). To assess acceptable clinical agreement between instruments, we used methods from a recently
published systematic review and meta-analysis on the use of
actigraphy from an AASM-commissioned task force [47] that
defined clinically significant thresholds of agreement based on
clinical expertise of the task force. These guidelines establish
minimum thresholds of agreement between sleep instruments
for diagnostic purposes (i.e. measurement differences between
devices do not change a diagnosis); this level of precision may
not be adequate for research purposes. The clinically significant
thresholds of agreement were determined between objective instruments (actigraphy vs. PSG) using 95% CIs of the mean difference, and objective vs. subjective instruments (actigraphy
vs. sleep logs) using the mean difference. Since there were no
published criteria comparing scEEG to actigraphy or scEEG to
diary, we applied the standard for PSG to scEEG. Following this
criteria, the maximum allowable 95% CIs of the mean difference
between objective instruments were 40 minutes for TST, 5% for
SE, 30 minutes for SOL, and 30 minutes for WASO. A 95% CI of
the mean difference within these limits is considered narrow
enough that the two objective instruments do not have clinically
significant differences and can be used interchangeably to provide consistent, objective sleep measurements. A 95% CI above
these limits is considered a clinically significant difference. The
allowable mean differences between objective and subjective instruments were 20 minutes for TST, 2.5% for SE, 15 minutes for
SOL, and 15 minutes for WASO. A difference above these thresholds is considered a clinically significant difference such that
diaries cannot be considered as providing similar data as the
objective method and it is recommended to use an objective instrument to provide the measurement.

Participant characteristics are shown in Table 1. A total of 293
participants had data available for all three instruments. The
mean age was 72.8 years (standard deviation [SD] = 10.1); 136
Table 1. Participant characteristics

Variable
Age (years, N = 293)
Sex (N = 293)
Male
Female
AHI (events/hour, N = 287)
Negative (AHI <5)
Mild (AHI 5–15)
Moderate (AHI 15–30)
Severe (AHI ≥30)
Lowest O2 saturation
(%, N = 287)
PLMI (events/hour, N = 284)
Negative (PLMI <15)
Low (PLMI 15–45)
High (PLMI ≥45)
CDR (N = 235)
CDR 0
CDR 0.5
MMSE (N = 235)
Normal cognition
(MMSE ≥27)
Mild cognitive impairment
(MMSE <27)
p-tau/Aβ42 (N = 109)
Low p-tau/Aβ42 (≤0.0198)
High p-tau/Aβ42 (>0.0198)

Mean (σ) or
n (%)
72.8 (10.1)
--136 (46.4%)
157 (53.6%)
8.98 (9.39)
131 (45.6%)
103 (35.9%)
42 (14.6%)
11 (3.83%)
82.2 (6.85)
24.4 (26.4)
150 (52.8%)
68 (23.9%)
66 (23.2%)
--192 (81.7%)
43 (18.3%)
28.8 (1.64)
212 (90.2%)

Range
61–91
---

0–48.9

53–93%
0–121.8

---

21–30

23 (9.8%)
0.0264 (0.0264)
64 (58.7%)
45 (41.3%)

0.00733–0.166

N = number of participants with available data for specified variable.
AHI = apnea/hypopnea index. PLMI = periodic limb movement index.
CDR = Clinical Dementia Rating. MMSE = Mini Mental State Examination. p-tau/
Aβ42 = ratio of cerebrospinal fluid phosphorylated tau to amyloid-β-42 peptide.
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Additionally, participants underwent a one-night home sleep
apnea test (HSAT) (Alice PDx, Philips Respironics) to assess for
sleep-disordered breathing or periodic limb movements during
sleep. Those already using positive airway pressure (PAP) therapy
were instructed to continue treatment during monitoring with
the HSAT. All recordings were reviewed by a board-certified sleep
physician.

3

4

| SLEEPO, 2020, Vol. 1, No. 1
demonstrated average SE, SOL, and WASO at the borderline or
sufficient to meet criteria for insomnia [52–54]. SE was <90% for
scEEG (78.7%), actigraphy (80.9%), and diary (89.3%). SOL measurements clustered around 20 minutes for each night (mean
SOL for scEEG: 17.6 minutes; actigraphy: 21.9 minutes; sleep
diary: 21.3 minutes). WASO measurements were close to 1 hour
for each night (mean WASO for scEEG: 71.6 minutes; actigraphy:
56.6 minutes; sleep diary: 41.6 minutes).

Agreement between sleep instruments
Sleep parameters
Mean sleep parameters are shown for the average of all available nights in Table 2. The average sleep parameters for individual nights are shown in Supplementary Table 1, the number
of participants with 2, 3, 4, 5, or 6 nights of sleep monitoring
are shown in Supplementary Table 2, and the number of participants with data available and correlations for individual nights
are shown in Supplementary Table 3. Our study population
Table 2. Average sleep parameters for each instrument
Mean (SD)
scEEG
TST (minutes)
SE (%)
SOL (minutes)
WASO (minutes)
Actigraphy
TST (minutes)
SE (%)
SOL (minutes)
WASO (minutes)
Diary
TST (minutes)
SE (%)
SOL (minutes)*
WASO (minutes)

373.7 (59.1)
78.7 (9.3)
17.6 (12.4)
80.0 (46.5)
390.6 (58.0)
80.9 (8.4)
21.9 (21.1)
56.6 (23.1)
435 (63.3)
89.3 (10.5)
24.7 (21.3)
41.6 (83.0)

*There were 289 participants with Diary SOL and WASO; other sleep parameters
were available for all 293 participants.

To assess agreement between instruments, we compared the
mean differences and 95% CIs between each instrument according to previously published criteria [47]. The ranges of the
95% CIs between scEEG and actigraphy were within the cutoffs
for TST, SE, SOL, and WASO to not be considered clinically significant differences (Table 3). However, when comparing the scEEG
or actigraphy to the diary, mean differences for TST and SE were
clinically significant (Table 3). On the other hand, the mean differences for SOL and WASO between scEEG or actigraphy and
the diary were not clinically significant. Although several of the
comparisons were deemed clinically significant by this criteria,
we note that there was a statistical difference for all comparisons except for SOL measured by actigraphy and diary (p = 0.063,
Table 3).
ICCs between scEEG, actigraphy, and sleep diary for the averaged sleep parameters are shown in Table 4. Relative to other
parameters, TST measurements showed the greatest agreement
between instruments for all six nights, with moderate agreement between scEEG vs. actigraphy (ICC = 0.694), poor agreement
between scEEG vs. diary (ICC = 0.472), and moderate agreement
between actigraphy vs. diary (ICC = 0.584). However, for SE, SOL,
and WASO, the instruments consistently showed weak agreement (ICCs < 0.5). All ICCs were significantly different from zero
(p < 0.05).
We further assessed inter-instrument agreement for each
sleep parameter using Bland-Altman plots, with the mean difference denoted with a solid blue line and the 95% limits of
agreement marked by dashed lines (Figures 1 and 2). Limits of

Table 3. Mean differences and paired t-tests
95% CI of mean difference

scEEG—actigraphy
TST (minutes)
SE (%)
SOL (minutes)
WASO (minutes)
scEEG—diary
TST (minutes)
SE (%)
SOL (minutes)
WASO (minutes)
Actigraphy—diary
TST (minutes)
SE (%)
SOL (minutes)
WASO (minutes)

Mean difference

Lower

Upper

95% CI range

P

−16.94
−2.14
−4.28
23.42

−23.31
−3.34
−6.67
18.05

−10.57
−0.93
−1.88
28.79

12.74
2.41
4.79
10.74

<0.0001
0.001
0.001
<0.0001

−61.84
−10.55
−7.21
37.40

−69.12
−12.03
−9.53
26.99

−54.56
−9.07
−4.89
47.82

14.56
2.96
4.64
20.86

<0.0001
<0.0001
<0.0001
<0.0001

−44.90
−8.41
−2.95
14.70

−51.71
−9.89
−6.06
5.26

−38.09
−6.94
0.17
24.15

13.62
2.95
6.23
18.62

<0.0001
<0.0001
0.063
0.002

Bold = No clinically meaningful differences between instruments. Italics = Clinically meaningful differences between instruments.
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(46.4%) participants were male. Overall, the average apneahypopnea index was mild (mean 8.98 events/hour, SD = 9.39)
as was the average periodic limb movement index (mean 24.4
events/hour, SD = 26.4). 235 participants had scores available
for CDR and MMSE. 81.7% of participants were CDR 0 and 90.2%
of participants had a MMSE ≥27, often considered to represent
normal cognition [51]. CSF p-tau/Aβ42 data was available for 109
participants. 58.7% of participants had a low CSF p-tau/Aβ42,
indicating no evidence of AD brain pathology [45].
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Table 4. Intraclass correlation coefficients based on average of all available nights from all participants
Comparison

F(df)

P

0.694 (0.595–0.766)
0.472 (−0.057–0.707)
0.584 (0.177–0.761)

F(292,292) 3.47
F(292,292) 2.74
F(292,292) 3.21

<0.0001
<0.0001
<0.0001

0.456 (0.316–0.567)
0.194 (−0.046–0.378)
0.137 (−0.052–0.297)

F(292,292) 1.87
F(292,292) 1.40
F(292,292) 1.23

<0.0001
0.002
0.040

0.428 (0.282–0.545)
0.479 (0.322–0.598)
0.333 (0.161–0.470)

F(292,292) 1.78
F(288,288) 2.04
F(288,288) 1.50

<0.0001
<0.0001
0.0003

0.276 (0.074–0.433)
0.159 (−0.036–0.320)
0.181 (−0.026–0.347)

F(292,292) 1.48
F(288,288) 1.22
F(288,288) 1.23

0.0005
0.045
0.041

*p < 0.05; **p < 0.01;***p < 0.0001.

Figure 1. Bland-Altman plots. Each graph shows the comparison between the average total sleep time (A–C) and sleep efficiency (D–F) (x-axis) and the difference in
total sleep time and sleep efficiency (y-axis) measured by two instruments. The blue line represents the mean bias between the instruments. The dotted lines denote
the 95% limits of agreement. Each row represents a different sleep parameter in comparing single-channel EEG (scEEG) and actigraphy, scEEG and diary, and actigraphy
and diary. Axes are standardized across rows. A–C: Total sleep time (TST). D–F: Sleep efficiency (SE).

agreement appeared to be wide across all plots. For each sleep
parameter, 95% limits of agreement were similarly wide between instrument comparisons, except for WASO, which demonstrated much wider 95% limits for diary comparisons. The
most striking observation from these plots is that the bias

between instruments increased with indicators of worsening
sleep: the data distribution widened with worsening SE <85%,
SOL > 20, WASO > 60 minutes for all instrument comparisons.
This pattern of increasing bias with worsening sleep was not
apparent for TST.
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Total sleep time
scEEG vs. actigraphy
scEEG vs. diary
Actigraphy vs. diary
Sleep efficiency
scEEG vs. actigraphy
scEEG vs. diary
Actigraphy vs. diary
Sleep onset latency
scEEG vs. actigraphy
scEEG vs. diary
Actigraphy vs. diary
Wake after sleep onset
scEEG vs. actigraphy
scEEG vs. diary
Actigraphy vs. diary

ICC (95% CI)
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Effect of cognitive status on agreement between
instruments
We compared instrument agreement between CDR and MMSE
groups. CDR is the gold standard for defining cognitive status in
AD, but MMSE is frequently used in previous studies comparing
different instruments that measure sleep. When assessed by
t-test, the majority of instrument comparisons for TST, SE, SOL,
and WASO were statistically different, especially in the CDR 0
and MMSE ≥27 groups (Table 5). The mean differences for all four
parameters in CDR 0 and MMSE ≥27 participants had sufficiently
narrow 95% CI that scEEG and actigraphy had no clinically significant differences (Table 5). However, for CDR 0.5 and MMSE
<27 individuals, the 95% CI widened for all parameters such
that there were clinically significant differences in TST, SE, and
WASO for scEEG vs. actigraphy. For the diary comparisons, 2 out
of 4 parameters in CDR 0 and MMSE ≥27 groups had clinically
significant differences, whereas 3 out of 4 parameters in CDR
0.5 and MMSE <27 groups had clinically significant differences.
The mean differences were overall greater in magnitude in the
CDR 0.5 and MMSE <27 groups. Of the instrument comparisons
deemed to have no clinically significant differences, only six
mean differences were not statistically significant: SOL (scEEG
vs. actigraphy in the CDR 0 and MMSE ≥27 groups; scEEG vs. diary
in CDR 0.5 and MMSE <27 groups; actigraphy vs. diary in CDR 0.5
group) and WASO (actigraphy vs. diary in CDR 0.5 group).

ICCs were generally greater for TST, SE, SOL, and WASO in
the CDR 0 and the MMSE ≥27 groups compared to the CDR 0.5
and MMSE <27 groups (Table 6). However, the 95% CIs overlapped between CDR and MMSE groups. For TST, all ICC comparisons between groups and instruments were significantly
different from zero. Also, ICCs for scEEG vs. actigraphy exceeded 0.7 in cognitively normal participants for TST. For SE,
in the CDR 0.5 and MMSE <27 groups, ICCs were not significantly different from zero for all instrument comparisons. SOL
and WASO were found to have variable results depending on
the instrument comparisons. For instance, the ICCs for scEEG
vs. actigraphy measurements of SOL were significantly different from zero in the CDR 0 and CDR 0.5 groups but not the
MMSE <27 group (Table 6). In contrast, SOL comparisons between scEEG vs. diary were greater in the CDR 0.5 and MMSE
<27 groups. For WASO, only the ICCs for scEEG vs. actigraphy
comparison in the CDR 0 and MMSE groups were significantly
different from zero.
Finally, we tested if there were group differences within instruments for TST, SE, SOL, and WASO. For scEEG, there were no
statistically significant group differences between CDR or MMSE
groups (Table 7). For actigraphy, SE, SOL, and WASO were found
to have significant mean differences between CDR and MMSE
groups. In contrast, for the sleep diary, only TST was significantly different between CDR and MMSE groups.
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Figure 2. Bland-Altman plots. Each graph shows the comparison between the average sleep onset latency (A–C) and wake after sleep onset (D–F) (x-axis) and the difference in sleep onset latency and wake after sleep onset (y-axis) measured by two instruments. The blue line represents the mean bias between the instruments. The
dotted lines denote the 95% limits of agreement. Each row represents a different sleep parameter in comparing single-channel EEG (scEEG) and actigraphy, scEEG and
diary, and actigraphy and diary. Axes are standardized across rows. A–C: Sleep Onset Latency (SOL). D–F: Wake After Sleep Onset (WASO).
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Table 5. Mean differences and paired t-tests for cognitive and AD biomarker groups

Lower

Upper

95% CI
range

P

CDR 0
scEEG—actigraphy
TST (minutes)
SE (%)
SOL (minutes)
WASO (minutes)
scEEG—diary
TST (minutes)
SE (%)
SOL (minutes)
WASO (minutes)
Actigraphy—diary
TST (minutes)
SE (%)
SOL (minutes)
WASO (minutes)

Upper

95% CI
range

P

−19.30
−2.83
−2.11
22.39

−23.75
−4.11
−4.82
16.51

−12.83
−1.54
0.60
28.27

10.92
2.57
5.42
11.76

<0.0001
<0.0001
0.127
<0.0001

−11.64
−1.42
−9.86
18.03

−34.37
−5.63
−16.54
1.48

11.09
2.80
−3.18
34.58

45.46
8.43
13.36
33.10

0.308
0.501
0.005
0.033

−55.76
−10.27
−7.65
34.71

−63.69
−12.00
−10.25
22.34

−47.84
−8.53
−5.04
47.08

15.85
3.47
5.21
24.74

<0.0001
<0.0001
<0.0001
<0.0001

−84.09
−13.76
−2.66
41.65

−103.38
−18.12
−6.78
11.36

−64.80
−9.41
1.46
71.95

38.58
8.71
8.24
60.59

<0.0001
<0.0001
0.199
0.008

−37.51
−7.57
−5.64
13.25

−45.22
−9.28
−9.47
2.07

−29.80
−5.86
−1.80
24.44

15.42
3.42
7.67
22.37

<0.0001
<0.0001
0.004
0.020

−70.51
−12.08
7.16
25.13

−87.27
−15.90
−0.24
−1.74

−53.75
−8.27
14.56
52.00

33.52
7.63
14.8
53.74

<0.0001
<0.0001
0.058
0.066

MMSE <27

−21.54
−3.14
−2.39
23.96

−28.18
−4.44
−5.05
18.11

−14.90
−1.83
0.26
29.81

13.28
2.61
5.31
11.70

<0.0001
<0.0001
0.077
<0.0001

15.63
3.39
−15.93
−1.06

−14.36
−2.44
−24.08
−23.73

45.63
9.23
−7.78
21.61

59.99
11.67
16.30
45.34

0.291
0.241
0.001
0.924

−59.68
−10.63
−7.51
36.21

−67.66
−12.38
−10.01
23.96

−51.70
−8.88
−5.00
48.46

15.96
3.50
5.01
24.50

<0.0001
<0.0001
<0.0001
<0.0001

−73.72
−12.49
−3.19
33.11

−99.49
−17.76
−8.41
4.46

−47.94
−7.21
2.04
61.75

51.55
10.55
10.45
57.29

<0.0001
<0.0001
0.217
0.026

−38.14
−7.50
−5.04
12.80

−45.34
−9.11
−8.67
1.87

−30.94
−5.88
−1.42
23.73

14.40
3.23
7.25
21.86

<0.0001
<0.0001
0.007
0.022

−89.35
−15.88
13.47
42.39

−113.85
−21.17
3.61
13.90

−64.84
−10.59
23.33
70.88

49.01
10.58
19.72
56.98

<0.0001
<0.0001
0.010
0.006

Low p-tau/Aβ42
scEEG—actigraphy
TST (minutes)
SE (%)
SOL (minutes)
WASO (minutes)
scEEG—diary
TST (minutes)
SE (%)
SOL (minutes)
WASO (minutes)
Actigraphy—diary
TST (minutes)
SE (%)
SOL (minutes)
WASO (minutes)

Lower

CDR 0.5

MMSE ≥27
scEEG—actigraphy
TST (minutes)
SE (%)
SOL (minutes)
WASO (minutes)
scEEG—diary
TST (minutes)
SE (%)
SOL (minutes)
WASO (minutes)
Actigraphy—diary
TST (minutes)
SE (%)
SOL (minutes)
WASO (minutes)

Mean
difference

95% CI of mean
difference

High p-tau/Aβ42

−27.15
−4.18
0.09
29.31

−37.82
−6.35
−3.10
19.55

−16.47
−2.01
3.27
39.08

21.35
4.34
6.37
19.53

<0.0001
<0.0001
0.957
<0.0001

−28.03
−4.43
−3.76
31.82

−45.82
−7.57
−8.84
18.15

−10.23
−1.29
1.33
45.50

35.59
6.28
10.17
27.35

0.003
0.007
0.144
<0.0001

−73.04
−12.52
−4.50
44.23

−86.21
−15.58
−8.52
18.65

−59.86
−9.46
−0.48
69.81

26.35
6.12
8.04
51.16

<0.0001
<0.0001
0.029
0.001

−63.92
−10.83
−5.55
40.75

−82.48
−14.43
−10.07
15.10

−45.37
−7.23
−1.03
66.40

37.11
7.20
9.04
51.30

<0.0001
<0.0001
0.017
0.003

−45.49
−8.23
−5.12
16.36

−57.01
−11.12
−10.29
−7.50

−33.98
−5.36
0.05
40.21

23.03
5.76
10.34
47.71

<0.0001
<0.0001
0.052
0.175

−38.71
−6.97
−1.71
9.12

−54.26
−10.14
−7.93
−13.92

−23.16
−3.80
4.52
32.16

31.10
6.34
12.45
46.08

<0.0001
<0.0001
0.583
0.429

N = number of participants in selected cognitive group. Bold = No clinically meaningful differences between instruments. Italics = Clinically significant differences
between instruments.

Bland-Altman plots for CDR and MMSE groups demonstrated wider 95% limits of agreement for scEEG vs. actigraphy
in CDR 0.5 and MMSE <27 groups, most noticeably for TST and
SE (Supplementary Figures 7–14). CDR and MMSE status did not
show a consistent pattern of change for the 95% limits for diary
comparisons. These results should be interpreted with caution
given the large discrepancy in group sizes.

Effect of AD pathology on agreement between
instruments
Statistically significant differences by t-test were found between most instrument comparisons in both p-tau/Aβ42 groups
(Table 5). No clinically significant differences were found for
scEEG vs. actigraphy in the low and high p-tau/Aβ42 groups, except for SE in the high group. However, the 95% CI were wider in
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Table 6. Intraclass correlation coefficients based on average of all available nights by group
CDR 0.5

MMSE ≥ 27

MMSE < 27

Low p-tau/Aβ42

High p-tau/Aβ42

ICC (95% CI)

ICC (95% CI)

ICC (95% CI)

ICC (95% CI)

ICC (95% CI)

ICC (95% CI)

F(df), P

F(df), P

F(df), P

F(df), P

F(df), P

F(df), P

0.488 (0.061–0.721)
F(42,42) 1.96,
0.016
0.472 (−0.221–0.771)

0.731 (0.584–0.817)
F(211,211) 4.22,
<0.0001
0.479 (−0.080–0.720)

0.705 (0.316–0.874)
F(22,22) 3.41,
0.003
0.605 (−0.212–0.862)

0.760 (0.456–0.878)
F(63,63) 5.40,
<0.0001
0.427 (−0.211–0.729)

0.564 (0.210–0.760)
F(44,44) 2.53,
0.001
0.521 (−0.144–0.784)

<0.0001
0.628 (0.277–0.784)
F(191,191) 3.47,
<0.0001

F(42,42) 3.48,
<0.0001
0.489 (−0.215–0.780)
F(42,42) 3.54,
<0.0001

F(211,211) 2.86,
<0.0001
0.632 (0.256–0.792)
F(211,211) 3.60,
<0.0001

F(22,22) 4.81,
0.0003
0.414 (−0.233–0.764)
F(22,22) 3.43,
0.003

F(63,63) 3.11,
<0.0001
0.599 (−0.043–0.818)
F(63,63) 3.93,
<0.0001)

F(44,44) 3.31,
<0.0001
0.716 (0.265–0.870)
F(44,44) 4.87,
<0.0001

Sleep efficiency
scEEG vs.
0.550 (0.395–0.664)
actigraphy F(191,191) 2.32,
<0.0001

0.236 (−0.418–0.587)
F(42,42) 1.31,
0.195

0.500 (0.334–0.623)
F(211,211) 2.10,
<0.0001

0.423 (−0.325–0.752)
F(22,22) 1.75,
0.099

0.527 (0.207–0.717)
F(63,63) 2.36,
0.0004

0.398 (−0.041–0.660)
F(44,44) 1.76,
0.033

0.202 (−0.061–0.403)
F(191,191) 1.42,
0.008
0.179 (−0.054–0.365)
F(191,191) 1.30,
0.035

0.116 (−0.224–0.416)
F(42,42) 1.25,
0.234
0.256 (−0.179–0.560)
F(42,42) 1.66,
0.052

0.183 (−0.063–0.375)
F(211,211) 1.37,
0.011
0.232 (−0.008–0.416)
F(211,211),
0.006

0.109 (−0.313–0.493)
F(22,22) 1.24,
0.306
0.048 (−0.243–0.386)
F(22,22) 1.13,
0.387

0.187 (−0.154–0.456)
F(63,63) 1.46,
0.069
0.138 (−0.214–0.417)
F(63,63) 1.24,
0.198

0.161 (−0.204–0.460)
F(44,44) 1.36,
0.156
0.383 (−0.066–0.652)
F(44,44) 1.88,
0.020

Sleep onset latency
scEEG vs.
0.482 (0.313–0.609)
actigraphy F(191,191) 1.94,
<0.0001
scEEG vs.
0.508 (0.306–0.647)
diary
F(189,189) 2.22,
<0.0001
Actigraphy 0.219 (−0.029–0.409)
vs. diary
F(189,189) 1.29,
0.040

0.374 (−0.087–0.649)
F(42,42) 1.69,
0.046
0.764 (0.561–0.873)
F(40,40) 4.29,
<0.0001
0.409 (−0.068–0.679)
F(40,40) 1.74,
0.042

0.493 (0.336–0.612)
F(211,211) 1.98,
<0.0001
0.542 (0.362–0.667)
F(210,210) 2.38,
<0.0001
0.269 (0.048–0.440)
F(210,210) 1.38,
0.010

0.194 (−0.340–0.584)
F(22,22) 1.40,
0.217
0.623 (0.080–0.849)
F(19,19) 2.70,
0.018
−0.044 (−0.871–0.507)
F(19,19) 0.942,
0.551

0.610 (0.356–0.764)
F(63,63) 2.54,
0.0002
0.667 (0.451–0.799)
F(62,62) 3.15,
<0.0001
0.313 (−0.110–0.579)
F(62,62) 1.48,
0.063

0.531 (0.158–0.740)
F(44,44) 2.16,
0.006
0.552 (0.198–0.752)
F(43,43) 2.36,
0.003
0.520 (0.115–0.739)
F(43,43) 2.06,
0.010

Wake after sleep onset
scEEG vs.
0.386 (0.140–0.556)
actigraphy F(191,191) 1.80,
<0.0001
scEEG vs.
0.158 (−0.086–0.351)
diary
F(189,189) 1.22,
0.09
Actigraphy 0.186 (−0.077–0.385)
vs. diary
F(189,189) 1.23,
0.075

0.058 (−0.621–0.0469)
F(42,42) 1.07,
0.417
−0.031 (−0.718–0.411)
F(40,40) 0.965,
0.544
0.118 (−0.578–0.517)
F(40,40) 1.14,
0.339

0.351 (0.105–0.525)
F(211,211) 1.71,
<0.0001
0.122 (−0.114–0.312)
F(210,210) 1.16,
0.141
0.188 (−0.059–0.378)
F(210,210) 1.24,
0.063

0.195 (−0.997–0.665)
F(22,22) 1.23,
0.315
0.038 (−0.881–0.569)
F(19,19) 1.05,
0.459
−0.004 (−0.733–0.513)
F(19,19) 0.995,
0.505

0.469 (0.022–0.702)
F(63,63) 2.37,
0.0004
0.194 (−0.237–0.489)
F(62,62) 1.28,
0.165
0.224 (−0.271–0.528)
F(62,62) 1.29,
0.157

0.146 (−0.290–0.471)
F(44,44) 1.25,
0.235
0.050 (−0.527–0.438)
F(43,43) 1.06,
0.421
0.028 (−0.793–0.472)
F(43,43) 1.03,
0.463

Group

Total sleep time
scEEG vs.
0.780 (0.660–0.851)
actigraphy F(191,191) 5.14,
<0.0001
scEEG vs.
0.520 (−0.048–0.749)
diary
F(191,191) 3.12,
Actigraphy
vs. diary

scEEG vs.
diary
Actigraphy
vs. diary

the high group than the low group. For the diary comparisons,
scEEG vs. diary TST, SE, and WASO, as well as actigraphy vs. diary
TST and SE were found to have clinically significant differences
in both low and high p-tau/Aβ42 groups. The mean differences
between low and high groups were similar.
Unlike the CDR and MMSE groups, ICCs were not generally
greater for TST, SE, SOL, and WASO in the low p-tau/Aβ42 group
(Table 6). For TST, all ICCs for the three instrument comparisons
were significantly different from zero but the 95% CIs overlapped. For SE, scEEG vs. diary comparisons in both low and high
p-tau/Aβ42 groups were not significantly different from zero
as was the actigraphy vs. diary comparison in the low p-tau/
Aβ42 group. For SOL, interestingly, the actigraphy vs. diary comparison in the low p-tau/Aβ42 group was not significantly different from zero in contrast to the high p-tau/Aβ42 group. For
WASO, only the ICC for the scEEG vs. actigraphy comparison in
the low p-tau/Aβ42 group was significantly different from zero.
Finally, testing for group differences within instruments, there

were no significant differences for TST, SE, SOL, or WASO between the low and high p-tau/Aβ42 groups (Table 7).
Similar to CDR and MMSE, Bland-Altman plots showed wider
95% limits of agreement for scEEG vs. actigraphy in the high
p-tau/Aβ42 group for TST, SE, SOL, and WASO (Supplementary
Figures 15–18). For scEEG vs. diary or actigraphy vs. diary, the
high p-tau/Aβ42 group showed wider limits for TST, similar
limits to the low group for SE and SOL, and narrower 95% limits
for WASO.

Discussion
In this study, we compared sleep parameters obtained via
scEEG, actigraphy, and sleep diary in a cognitively normal and
mildly symptomatic older adult population. We took a multifaceted approach to assessing instrument agreement. First, we
used paired t-tests to assess differences between instruments
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Table 7. Group differences in sleep measures within devices
Group

MMSE ≥27 vs. MMSE <27

Low vs. High p-tau/Aβ42

F(df)

P

F(df)

P

F(df)

P

F(1,233) 0.042
F(1,233) 1.152
F(1,233) 0.421
F(1,233) 0.476

0.837
0.284
0.517
0.491

F(1,233) 3.413
F(1,233) 0.115
F(1,233) 0.064
F(1,233) 0.394

0.066
0.735
0.801
0.531

F(1,107) 0.716
F(1,107) 0.237
F(1,107) 0.246
F(1,107) 0.097

0.399
0.627
0.621
0.756

F(1,233) 0.115
F(1,233) 3.873
F(1,233) 5.78
F(1,233) 3.987

0.735
0.050
0.017
0.047

F(1,233) 1.106
F(1,233) 10.862
F(1,233) 8.357
F(1,233) 13.916

0.294
0.001
0.004
0.00024

F(1,107) 0.866
F(1,107) 0.440
F(1,107) 0.839
F(1,107) 1.354

0.354
0.508
0.362
0.247

F(1,233) 9.36
F(1,233) 1.187
F(1,229) 1.997
F(1,229) 0.105

0.002
0.277
0.159
0.747

F(1,233) 8.84
F(1,233) 1.276
F(1,229) 1.589
F(1,229) 0.428

0.003
0.260
0.209
0.514

F(1,107) 0.058
F(1,107) 0.024
F(1,105) 0.018
F(1,105) 0.015

0.810
0.878
0.892
0.904

and found that most differences were statistically significant.
However, using a published criteria defining clinically significant differences when comparing sleep parameters between
different instruments via paired t-tests [47], we found that differences between scEEG and actigraphy were not clinically significant. This suggests that the apparent differences between
scEEG and actigraphy are consistent enough that these two
instruments can potentially be used to measure TST, SE, SOL,
and WASO after accounting for their biases in a clinical setting
for diagnostic purposes. If greater precision is necessary in a
research setting, these differences may not be permissible. We
found that sleep diaries may provide similar measurements to
either scEEG or actigraphy for SOL and WASO but not for TST
and SE, suggesting that sleep diaries capture different aspects
of these sleep parameters. Perceived sleep quality, though not
formally assessed in our participants, certainly influences sleep
diary entries and is an important facet of a comprehensive
clinical sleep evaluation. The discrepancy between objective
and subjective methods is consistent with patterns in previous
studies and may reflect the observation that objective sleep
assessment poorly predicts subjective sleep quality [27–34].
This discrepancy between objective sleep measures, such as
polysomnography, and subjective sleep quality has led to the
suggestion that polysomnography should not be considered
the gold standard for sleep measurement [35]. Different sleep
measurement methods may capture different aspects of sleep
quality and argue for using a multi-modal approach for assessing sleep-wake activity.
We also found that TST overall had the greatest agreement
between instruments, although the ICCs ranged from 0.694 for
scEEG vs. actigraphy comparisons (moderate agreement) to 0.472
for scEEG vs. diary comparisons (poor agreement). SE, SOL, and
WASO showed poor agreement as measured by ICC. Previous
work in young to middle-aged adults comparing actigraphy
and sleep diaries has also found TST to be more strongly correlated between instruments than parameters such as SE, SOL,
and WASO [28, 36]. In a previous study, we compared the scEEG
to PSG and found excellent reliability between the measures for
TST (ICC = 0.96), good reliability for SE (ICC = 0.86) and WASO
(ICC = 0.79), and moderate reliability for SOL (ICC = 0.67) [20].
Although we did not compare actigraphy and sleep diaries to
PSG in this study, our previous study suggests that scEEG is an

excellent approximation of TST, SE, and WASO as measured
by PSG.
Consistent with studies in other populations [20, 32, 34, 55,
56], Bland-Altman plots identified that quantitative markers of
worsened sleep, such as lower SE, higher SOL, and higher WASO,
resulted in increased disagreement between instruments.
Additionally, we observed wide 95% limits of agreement for
all sleep measures, which may not be acceptable for research
and/or clinical use. Other studies comparing objective and subjective instruments via this method of analysis have generally
deemed that agreement is poor, but interpretation of results has
been variable despite similar limits of agreement compared to
our findings [27, 34, 36, 37].
Our study also suggests that cognitive impairment as assessed
by CDR or MMSE and the presence of AD pathology measured by
the CSF p-tau/Aβ42 ratio worsens the agreement between scEEG
and actigraphy. Separating our participants by CDR or MMSE
status demonstrated a trend of worsening statistical and clinical
agreement in mildly symptomatic individuals, but this was not
consistent across all sleep parameters and instrument comparisons. This pattern was most prominently seen for comparisons
of scEEG vs. actigraphy and for measurements of TST. Most ICCs
were greater in CDR 0 and MMSE ≥27 groups, but the overlapping
CIs temper this observation. 95% limits of agreement from BlandAltman plots were wider for TST and SE in scEEG vs. actigraphy
for CDR 0.5 and MMSE <27 subgroups, but the small size of these
subgroups may limit this interpretation. The groups with and
without biomarker evidence of AD pathology (i.e. low and high
p-tau/Aβ42 ratio) did not show a clear trend in clinical agreement or ICCs, but the high p-tau/Aβ42 group did have wider 95%
limits of agreement from Bland-Altman plots for all four sleep
parameters in comparing scEEG vs. actigraphy. It is important to
note the greater sample size imbalance between CDR and MMSE
groups compared to the p-tau/Aβ42 groups. Thus, it may be necessary to exercise caution in comparing scEEG to actigraphy in
older adults with cognitive impairment and/or evidence of AD
pathology. It may be that scEEG and actigraphy provide different
information about sleep-wake activity in mildly impaired adults.
Some speculation as to the etiology of this phenomenon include
changes on sleep EEG architecture that are linked to the presence
of AD pathology [44] that would not be captured on actigraphy, as
well as the finding that actigraphy may be less accurate in older
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MMSE can be sensitive in detecting overt dementia, it does not
discriminate as well between CDR 0 and 0.5 [59], has a limited
role in identifying mildly impaired individuals if only administered once or in isolation of other tests [60, 61], and can be affected by education and age [51].
Our study demonstrated differences in agreement between
scEEG and actigraphy by cognitive status and biomarker evidence of AD pathology. scEEG and actigraphy showed reasonable
agreement for TST, SE, SOL, and WASO in cognitively normal
older adults, with the best agreement observed for TST. Caution
should be exercised when comparing these methods in mildly
symptomatic individuals or those with biomarker evidence of
AD pathology. Sleep diaries likely capture different aspects of
sleep compared to scEEG and actigraphy and are an important
component of a thorough sleep evaluation. Future work will
need to further investigate the relationship between sleep instruments and cognitive function and AD pathology, especially
using robust cognitive assessments (e.g. CDR) and AD biomarkers (e.g. CSF p-tau/Aβ42).

Limitations
There are several limitations to our study. First, we used
published criteria from an AASM-commissioned task force
[47] for comparing clinically significant agreement between
actigraphy vs. PSG and actigraphy vs. sleep diary, and extrapolated this criteria to the scEEG device. We considered these
criteria to be reasonable, but these may not be acceptable if
a good or excellent level of agreement is needed to achieve
the necessary precision of measurements by different instruments. Second, the majority of our participants were cognitively normal with ~20% showing evidence of symptomatic
AD. Third, only a limited number of patients had CSF data
available for analysis. Fourth, individuals who participate in
longitudinal biomarker studies of AD almost certainly are not
representative of the general population.

Supplementary material
Supplementary material is available at SLEEP Advances online.
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adults with sleep disturbances due to motionless wake being
scored incorrectly as sleep [57].
For the sleep diary, clinical agreement for the various sleep
parameters was already limited for CDR 0, MMSE ≥27, and low
p-tau/Aβ42, and differences between instruments appeared to
worsen slightly for CDR 0.5 and MMSE <27 groups, but not for
the high p-tau/Aβ42 group. Cognitively impaired groups or the
high p-tau/Aβ42 group was associated with lower ICCs and/
or ICCs not significantly different from zero. The 95% limits
of agreement via Bland-Altman plots did not show a consistent effect of CDR, MMSE, or p-tau/Aβ42 across different
sleep parameters in diary comparisons. These results hint
that cognitive status or biomarker evidence of AD pathology
may worsen the agreement of the sleep diary with scEEG or
actigraphy, but lack of consistently worsened agreement across
multiple analyses and multiple parameters makes this less
compelling. This may reflect the already inherent limitations of
sleep diaries in providing accurate numeric measurements of
sleep, independent of cognitive status or presence of AD pathology. Sleep diaries are prone to recall bias, may be filled out by
persons other than the participant, and require multiple days
of sustained adherence.
In general, prior work on the effect of cognition on sleep instrument agreement found that impaired cognition decreases
agreement between subjective and objective instruments.
A study of over 900 older adults found that cognitive function
assessed by the MMSE was associated with decreased agreement between actigraphy and diary-measured TST [58]. Other
studies have been limited by small sample sizes, such as one
study comparing PSG and sleep diaries in 25 cognitively normal
adults and 25 mildly impaired adults and found that only cognitively normal adults had significant relationships between
slow-wave sleep arousals on PSG and self-reported sleep disturbances [38]. Further, it was found that mildly impaired patients significantly misperceived SOL in comparing self-report to
PSG whereas cognitively normal adults did not. In another study,
55 people with early to moderate-stage AD were compared to
26 cognitively normal older adults and found that sleep questionnaires poorly predicted actigraphic results in both groups
[40]. However, MMSE scores did not correlate with subjectiveobjective differences suggesting that the discrepancy was not
related to cognitive functioning as assessed by the MMSE [40].
Another study in 59 older adults with cognitive impairment
and depression used an extensive battery of cognitive tests
(including MMSE, CDR, and other dementia-specific tests) and
found that delayed memory, but not level of executive functioning, was associated with increased discrepancy between
actigraphy and the Pittsburgh Sleep Quality Index [39]. However,
there have been several other studies that showed no effect
of cognition as measured by MMSE or the Montreal Cognitive
Assessment [31, 33].
Several previous studies did not find that MMSE score affected agreement between sleep parameters measured by different instruments [31, 33, 40], possibly due to smaller sample
sizes (<100 participants). The mixed results between the MMSE
groups in this study and previous studies signify the limited
utility of the MMSE as a screening tool compared to a comprehensive cognitive assessment. The CDR collects significantly
more information about multiple domains of daily living to
assess cognitive function compared to the MMSE, which is a
one-time battery of short neuropsychologic tests. Although the

Chou et al. |
12.

13.

14.

Acknowledgments
We are indebted to the participants for their contributions to
this study.

Disclosure Statement
This is not an industry-sponsored study. J.C.M. is funded by
NIH grants # P30 AG066444, P01AG003991; P01AG026276, U19
AG032438; and U19 AG024904. Neither Dr. Morris nor his family
owns stock or has equity interest (outside of mutual funds or
other externally directed accounts) in any pharmaceutical or
biotechnology company. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. consults for
Genentech, Idorsia, Merck, and Denali. Washington University
receives a research grant to the laboratory of D.M.H. from C2N
Diagnostics. B.P.L. consults for Merck. C.A.C., C.D.T., T.R., D.F.,
J.S.M.: declare that they have no financial disclosures. None of
the authors report any non-financial disclosures.

References
Jack CR Jr, et al. Tracking pathophysiological processes in
Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207–216.
2. Sperling RA, et al. Toward defining the preclinical stages of
Alzheimer’s disease: recommendations from the National
Institute on Aging-Alzheimer’s Association workgroups on
diagnostic guidelines for Alzheimer’s disease. Alzheimers
Dement. 2011;7(3):280–292.
3. Peter-Derex L, et al. Sleep and Alzheimer’s disease. Sleep Med
Rev. 2015;19:29–38.
4. Pollak CP, et al. Sleep problems and institutionalization of
the elderly. J Geriatr Psychiatry Neurol. 1991;4(4):204–210.
5. Ju YE, et al. Sleep and Alzheimer disease pathology–a bidirectional relationship. Nat Rev Neurol. 2014;10(2):115–119.
6. Musiek ES, et al. Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. Exp Mol Med. 2015;47:e148.
7. Ju YE, et al. Sleep quality and preclinical Alzheimer disease.
JAMA Neurol. 2013;70(5):587–593.
8. Naismith SL, et al. Circadian misalignment and sleep disruption in mild cognitive impairment. J Alzheimers Dis.
2014;38(4):857–866.
9. Hita-Yañez E, et al. Disturbed sleep patterns in elders
with mild cognitive impairment: the role of memory
decline and ApoE ε4 genotype. Curr Alzheimer Res.
2012;9(3):290–297.
10. Westerberg CE, et al. Sleep influences the severity of
memory disruption in amnestic mild cognitive impairment: results from sleep self-assessment and continuous
activity monitoring. Alzheimer Dis Assoc Disord. 2010;24(4):
325–333.
11. Drogos LL, et al. Evidence of association between sleep
quality and APOE ε4 in healthy older adults: a pilot study.
Neurology. 2016;87(17):1836–1842.

15.
16.

17.

18.

19.
20.
21.

22.

23.

1.

24.

25.
26.

27.

28.

29.

30.

31.

32.

33.

34.

Hu M, et al. Sleep disturbance in mild cognitive impairment: a systematic review of objective measures. Neurol Sci.
2017;38(8):1363–1371.
Palmer K, et al. Sleep disturbance in mild cognitive impairment and association with cognitive functioning. A casecontrol study. Front Aging Neurosci. 2018;10:360.
Gallicchio L, et al. Sleep duration and mortality: a systematic
review and meta-analysis. J Sleep Res. 2009;18(2):148–158.
Spiegelhalder K, et al. The association between insomnia
and cardiovascular diseases. Nat Sci Sleep. 2010;2:71–78.
Nakakubo S, et al. Long and short sleep duration and physical frailty in community-dwelling older adults. J Nutr
Health Aging. 2018;22(9):1066–1071.
Vaz Fragoso CA, et al. Sleep-wake disturbances and frailty
in community-living older persons. J Am Geriatr Soc.
2009;57(11):2094–2100.
Kushida CA, et al. Practice parameters for the indications
for polysomnography and related procedures: an update
for 2005. Sleep. 2005;28(4):499–521.
Agnew HW Jr, et al. The first night effect: an EEG study of
sleep. Psychophysiology. 1966;2(3):263–266.
Lucey BP, et al. Comparison of a single-channel EEG sleep
study to polysomnography. J Sleep Res. 2016;25(6):625–635.
Finan PH, et al. Validation of a wireless, self-application, ambulatory electroencephalographic sleep monitoring device
in healthy volunteers. J Clin Sleep Med. 2016;12(11):1443–1451.
Levendowski DJ, et al. The accuracy, night-to-night variability, and stability of frontopolar sleep electroencephalography biomarkers. J Clin Sleep Med. 2017;13(6):791–803.
Kushida CA,et al. Comparison of actigraphic, polysomnographic,
and subjective assessment of sleep parameters in sleepdisordered patients. Sleep Med. 2001;2(5):389–396.
Marino M, et al. Measuring sleep: accuracy, sensitivity, and specificity of wrist actigraphy compared to
polysomnography. Sleep. 2013;36(11):1747–1755.
Martin JL, et al.Wrist actigraphy. Chest. 2011;139(6):1514–1527.
Matsuo M, et al. Comparisons of portable sleep monitors
of different modalities: potential as naturalistic sleep recorders. Front Neurol. 2016;7:110.
Zhu B, et al. Sleep assessment in aging adults with type 2
diabetes: agreement between actigraphy and sleep diaries.
Sleep Med. 2018;46:88–94.
Thurman SM, et al. Individual differences in compliance
and agreement for sleep logs and wrist actigraphy: A longitudinal study of naturalistic sleep in healthy adults. PLoS
One. 2018;13(1):e0191883.
Williams JM, et al. Sleep discrepancy, sleep complaint, and
poor sleep among older adults. J Gerontol B Psychol Sci Soc Sci.
2013;68(5):712–720.
O’Donnell D, et al. Comparison of subjective and objective
assessments of sleep in healthy older subjects without
sleep complaints. J Sleep Res. 2009;18(2):254–263.
Landry GJ, et al. Measuring sleep quality in older adults: a
comparison using subjective and objective methods. Front
Aging Neurosci. 2015;7:166.
Kay DB, et al. Subjective-objective sleep discrepancy among
older adults: associations with insomnia diagnosis and insomnia treatment. J Sleep Res. 2015;24(1):32–39.
Hughes JM, et al. Measuring sleep in vulnerable older adults:
a comparison of subjective and objective sleep measures.
Clin Gerontol. 2018;41(2):145–157.
Chang ET, et al. Differences between sleep logs and actigraphy
combined with electroencephalography in adults with
sleep disturbances. Biol Res Nurs. 2018;20(1):77–83.

Downloaded from https://academic.oup.com/sleepadvances/article/1/1/zpaa006/5937495 by Washington University School of Medicine Library user on 13 October 2022

acquisition of data, analysis and interpretation of data, and revising of manuscript. D.M.H.: acquisition of data, analysis and
interpretation of data, and drafting of manuscript. B.P.L.: conception and design, acquisition of data, analysis and interpretation of data, and drafting of manuscript.

11

12
35.

37.

38.

39.

40.

41.
42.

43.
44.

45.

46.

47.

48.

Kaplan KA, et al.; Osteoporotic Fractures in Men (MrOS),
Study of Osteoporotic Fractures SOF Research Groups.
When a gold standard isn’t so golden: lack of prediction of
subjective sleep quality from sleep polysomnography. Biol
Psychol. 2017;123:37–46.
Campanini MZ, et al. Agreement between sleep diary and
actigraphy in a highly educated Brazilian population. Sleep
Med. 2017;35:27–34.
Moore CM, et al. Actigraphy and sleep diary measurements
in breast cancer survivors: discrepancy in selected sleep
parameters. Behav Sleep Med. 2015;13(6):472–490.
Hita-Yañez E, et al. Polysomnographic and subjective
sleep markers of mild cognitive impairment. Sleep.
2013;36(9):1327–1334.
DiNapoli EA, et al. Subjective-objective sleep discrepancy
in older adults with MCI and subsyndromal depression. J
Geriatr Psychiatry Neurol. 2017;30(6):316–323.
Most EI, et al. Discrepancy between subjective and objective
sleep disturbances in early- and moderate-stage Alzheimer
disease. Am J Geriatr Psychiatry. 2012;20(6):460–467.
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–2414.
Folstein MF, et al. Mini-mental state: a practical method for
grading the cognitive state of patients for the clinician. J
Psychiat Res. 1975;12(3):189–198.
Toedebusch CD, et al. Multi-modal home sleep monitoring
in older adults. J Vis Exp. 2019;143:e58823.
Lucey BP, et al. Reduced non-rapid eye movement sleep is
associated with tau pathology in early Alzheimer’s disease.
Sci Transl Med. 2019;11(474):eaau6550.
Schindler SE, et al. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.
Alzheimers Dement. 2018;14(11):1460–1469.
Fagan AM, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively
normal individuals: implications for future clinical trials of
Alzheimer’s disease. EMBO Mol Med. 2009;1(8-9):371–380.
Smith MT, et al. Use of actigraphy for the evaluation of sleep
disorders and circadian rhythm sleep-wake disorders: an
American academy of sleep medicine systematic review,
meta-analysis, and GRADE assessment. J Clin Sleep Med.
2018;14(7):1209–1230.
Fisher R. Statistical Methods for Research Workers. 5th ed.
Edinburgh, UK: Oliver & Boyd; 1954.

49.

50.

51.

52.
53.

54.

55.

56.

57.

58.

59.

60.

61.

Koo TK, et al. A guideline of selecting and reporting
intraclass correlation coefficients for reliability research. J
Chiropr Med. 2016;15(2):155–163.
Bland JM, et al. Statistical methods for assessing agreement
between two methods of clinical measurement. Lancet.
1986;1(8476):307–310.
O’Bryant SE, et al. Detecting dementia with the mini-mental
state examination in highly educated individuals. Arch
Neurol. 2008;65(7):963–967.
Lichstein KL, et al. Quantitative criteria for insomnia. Behav
Res Ther. 2003;41(4):427–445.
Lineberger MD, et al. Defining insomnia: quantitative criteria for insomnia severity and frequency. Sleep.
2006;29(4):479–485.
Levenson JC, et al. A quantitative approach to distinguishing
older adults with insomnia from good sleeper controls. J
Clin Sleep Med. 2013;9(2):125–131.
Kaplan KA, et al. Evaluating sleep in bipolar disorder:
comparison
between
actigraphy, polysomnography,
and
sleep
diary.
Bipolar
Disord.
2012;14(8):
870–879.
McCall C, et al. Comparison of actigraphy with
polysomnography and sleep logs in depressed insomniacs.
J Sleep Res. 2012;21(1):122–127.
Sivertsen B, et al. A comparison of actigraphy and
polysomnography in older adults treated for chronic primary insomnia. Sleep. 2006;29(10):1353–1358.
Van Den Berg JF, et al. Disagreement between subjective and actigraphic measures of sleep duration in a
population-based study of elderly persons. J Sleep Res.
2008;17(3):295–302.
Perneczky R, et al. Mapping scores onto stages: mini-mental
state examination and clinical dementia rating. Am J Geriatr
Psychiatry. 2006;14(2):139–144.
Arevalo-Rodriguez
I,
et
al.
Mini-Mental
State
Examination (MMSE) for the detection of Alzheimer’s disease and other dementias in people with mild cognitive
impairment (MCI). Cochrane Database Syst Rev. 2015;2015(3):
Cd010783.
Creavin ST, Wisniewski S, Noel-Storr AH, et al. Mini-Mental
State Examination (MMSE) for the detection of dementia in
clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst
Rev. 2016;(1):Cd011145.

Downloaded from https://academic.oup.com/sleepadvances/article/1/1/zpaa006/5937495 by Washington University School of Medicine Library user on 13 October 2022

36.

| SLEEPO, 2020, Vol. 1, No. 1

